Siliphos ® Clinical Studies Index

Read about studies conducted on Siliphos, the active ingredient in UltraThistle.

  • (Ref20C15) Effect of Siliphos® on chronic active hepatitis

    Study shows significant reduction in elevated liver enzymes (and therefore hepatocellular necrosis) in just one week of treatment with Siliphos®.

  • (Ref21C13) Therapeutic effect of Siliphos® in chronic liver disease

    A small study of eight human subjects with chronic active hepatitis. This study shows significant benefits of Siliphos® after just two months treatment.

  • (Ref8P22) Direct comparison of Siliphos® to standardized milk thistle extract

    Study shows nearly 10x the bioavailability of Siliphos® over the world's best selling standardized extract.

  • (Ref18C14) Useful dosages of Siliphos®:

    Shows definite advantages of Siliphos® at dosages ranging from 160mg to 360mg (measured as silybin). Dose/effect relationship is also demonstrated with the highest dosage tested getting the most dramatic results.

  • (c10) Considerably greater bioavailability of silybin as a component of Siliphos®:

    Laboratory study shows that binding silybin with phosphatidylcholine on a molecular level dramatically improves its bioavailablity on a cellular level.

  • (c3medline) Increased oral bioavailability of Siliphos® in humans:

    Human study compares Siliphos® and the worlds best selling standardized milk thistle extract and shows how much better the results are with Siliphos®.

  • (Ref9C8) Effect of Siliphos® on cirrhotic patients:

    Study shows that Siliphos® does not significantly differ in its safe and beneficial activity in patients with cirrhosis vs. healthy control subjects.

  • (Ref10C2) Long term usage of Siliphos®:

    Study shows the beneficial properties of Siliphos® are not diminished by sustained usage of the product.

  • (Ref12P19) Liver damage control properties of Siliphos®:

    Siliphos® shows significant protective activity against liver damage. This study tested Siliphos® protection against a variety of toxins.

  • (Ref13P6) Free radical scavenging properties of Siliphos®:

    Study shows the capability of Siliphos® to scavenge free radicals and inhibit lipid peroxidation. It also demonstrates significantly higher blood plasma levels of silybin when administered as a component of Siliphos® rather than in its unbound form.

  • (Ref14P13) Effect of silimarin on lipid peroxidation:

    Study shows milk thistle extract (silymarin) to be a helpful antioxidant and silybin to be the most valuable constituent of silymarin.

  • (Ref15P16) Siliphos® counteracts hepatotoxic effects:

    Study shows Siliphos® protects liver cells against free-radical mediated toxic liver injury.

  • (Ref16P23) Antioxidant activity of Siliphos® against alcohol:

    Study shows how Siliphos® is dramatically more effective than pure silybin alone. Concludes Siliphos® may be useful in counteracting damage caused by alcohol intake.

  • (Ref19C6) Tolerablility and effectiveness of Siliphos®:

    Study shows high dose tolerability of Siliphos® as well as its increased effectiveness over conventional standardized milk thistle extract.

  • (c6medline) Liver protection potential of Siliphos®:

    Study shows the antioxidant and free radical scavenging effect of Siliphos®.

  • (Ref7P12) Comparative bioavailability of Siliphos® vs. silybin:

    Study shows exactly how much better silybin is absorbed when combined on a molecular level with phosphatidylcholine (a patented process resulting in Siliphos®).

  • (Ref11P1) Liver protective activity:

    Shows Siliphos® is more effective than its constituents, silybin and phosphatidylcholine, alone. The effectiveness of Siliphos® is considerably greater than the sum of its parts.